Show simple item record

dc.contributor.authorvan Erp, AEMen_US
dc.contributor.authorVersleijen-Jonkers, YMHen_US
dc.contributor.authorHillebrandt-Roeffen, MHSen_US
dc.contributor.authorvan Houdt, Len_US
dc.contributor.authorGorris, MAJen_US
dc.contributor.authorvan Dam, LSen_US
dc.contributor.authorMentzel, Ten_US
dc.contributor.authorWeidema, MEen_US
dc.contributor.authorSavci-Heijink, CDen_US
dc.contributor.authorDesar, IMEen_US
dc.contributor.authorMerks, HHMen_US
dc.contributor.authorvan Noesel, MMen_US
dc.contributor.authorShipley, Jen_US
dc.contributor.authorvan der Graaf, WTAen_US
dc.contributor.authorFlucke, UEen_US
dc.contributor.authorMeyer-Wentrup, FAGen_US
dc.date.accessioned2017-09-04T10:44:07Z
dc.date.issued2017-07-07en_US
dc.identifier.citationOncotarget, 2017en_US
dc.identifier.issn1949-2553en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/808
dc.identifier.eissn1949-2553en_US
dc.identifier.doi10.18632/oncotarget.19071en_US
dc.description.abstractIn order to explore the potential of immune checkpoint blockade in sarcoma, we investigated expression and clinical relevance of programmed cell death-1 (PD-1), programmed death ligand-1 (PD-L1) and CD8 in tumors of 208 sarcoma patients. Primary untreated osteosarcoma (n = 46), Ewing sarcoma (n = 32), alveolar rhabdomyosarcoma (n = 20), embryonal rhabdomyosarcoma (n = 77), synovial sarcoma (n = 22) and desmoplastic small round cell tumors (DSRCT) (n = 11) were examined immunohistochemically. PD-L1 expression was predominantly detected in alveolar and embryonal rhabdomyosarcomas (15% and 16%, respectively). In the alveolar subtype PD-L1 expression was associated with better overall, event-free and metastases-free survival. PD-1 expression on lymphocytes was predominantly seen in synovial sarcomas (18%). High levels of CD8+ lymphocytes were predominantly detected in osteosarcomas (35%) and associated with worse event-free survival in synovial sarcomas. Ewing sarcoma and DSRCTs showed PD-1 on tumor cells instead of on tumor infiltrating lymphocytes. Overall, expression and clinical associations were found to be subtype dependent. For the first time PD-1 expression on Ewing sarcoma (19%) and DSRCT (82%) tumor cells was described.en_US
dc.formatPrint-Electronicen_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleExpression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-06-27en_US
rioxxterms.versionofrecord10.18632/oncotarget.19071en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en_US
rioxxterms.licenseref.startdate2017-07-07en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfOncotargeten_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Sarcoma Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Molecular Pathology
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.embargo.termsNo embargoen_US
icr.researchteamClinical and Translational Sarcomaen_US
icr.researchteamSarcoma Molecular Pathologyen_US
dc.contributor.icrauthorvan der Graaf, Wilhelminaen_US
dc.contributor.icrauthorShipley, Janeten_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/